TY - JOUR
T1 - Clinical research in ovarian cancer
T2 - consensus recommendations from the Gynecologic Cancer InterGroup
AU - participants of the 6th Gynecologic Cancer InterGroup (GCIG) Ovarian Cancer Consensus Conference on Clinical Research
AU - Vergote, Ignace
AU - Gonzalez-Martin, Antonio
AU - Lorusso, Domenica
AU - Gourley, Charlie
AU - Mirza, Mansoor Raza
AU - Kurtz, Jean Emmanuel
AU - Okamoto, Aikou
AU - Moore, Kathleen
AU - Kridelka, Frédéric
AU - McNeish, Iain
AU - Reuss, Alexander
AU - Votan, Bénédicte
AU - du Bois, Andreas
AU - Mahner, Sven
AU - Ray-Coquard, Isabelle
AU - Kohn, Elise C.
AU - Berek, Jonathan S.
AU - Tan, David S.P.
AU - Colombo, Nicoletta
AU - Zang, Rongyu
AU - Concin, Nicole
AU - O'Donnell, Dearbhaile
AU - Rauh-Hain, Alejandro
AU - Herrington, C. Simon
AU - Marth, Christian
AU - Poveda, Andres
AU - Fujiwara, Keiichi
AU - Stuart, Gavin C.E.
AU - Oza, Amit M.
AU - Bookman, Michael A.
AU - Grimm, Christoph
AU - Berger, Regina
AU - Chang, Ting Chang
AU - Ochiai, Kazunori
AU - Gebski, Val
AU - Davis, Alison
AU - Beale, Philip
AU - Denys, Hannelore
AU - Vandecaveye, Vincent
AU - Cancido dos Reis, Francisco Jose
AU - Del Pilar Estevez Diz, Maria
AU - Stuart, Gavin
AU - MacKay, Helen
AU - Carey, Mark
AU - Cibula, David
AU - Dundr (path), Pavel
AU - Dorigo, Oliver
AU - Berek, Jonathan
AU - Saadeh, Abu
AU - Boere, Ingrid
N1 - Publisher Copyright:
© 2022 Elsevier Ltd
PY - 2022/8
Y1 - 2022/8
N2 - The Gynecologic Cancer InterGroup (GCIG) sixth Ovarian Cancer Conference on Clinical Research was held virtually in October, 2021, following published consensus guidelines. The goal of the consensus meeting was to achieve harmonisation on the design elements of upcoming trials in ovarian cancer, to select important questions for future study, and to identify unmet needs. All 33 GCIG member groups participated in the development, refinement, and adoption of 20 statements within four topic groups on clinical research in ovarian cancer including first line treatment, recurrent disease, disease subgroups, and future trials. Unanimous consensus was obtained for 14 of 20 statements, with greater than 90% concordance in the remaining six statements. The high acceptance rate following active deliberation among the GCIG groups confirmed that a consensus process could be applied in a virtual setting. Together with detailed categorisation of unmet needs, these consensus statements will promote the harmonisation of international clinical research in ovarian cancer.
AB - The Gynecologic Cancer InterGroup (GCIG) sixth Ovarian Cancer Conference on Clinical Research was held virtually in October, 2021, following published consensus guidelines. The goal of the consensus meeting was to achieve harmonisation on the design elements of upcoming trials in ovarian cancer, to select important questions for future study, and to identify unmet needs. All 33 GCIG member groups participated in the development, refinement, and adoption of 20 statements within four topic groups on clinical research in ovarian cancer including first line treatment, recurrent disease, disease subgroups, and future trials. Unanimous consensus was obtained for 14 of 20 statements, with greater than 90% concordance in the remaining six statements. The high acceptance rate following active deliberation among the GCIG groups confirmed that a consensus process could be applied in a virtual setting. Together with detailed categorisation of unmet needs, these consensus statements will promote the harmonisation of international clinical research in ovarian cancer.
UR - http://www.scopus.com/inward/record.url?scp=85135243543&partnerID=8YFLogxK
U2 - 10.1016/S1470-2045(22)00139-5
DO - 10.1016/S1470-2045(22)00139-5
M3 - 文献综述
C2 - 35901833
AN - SCOPUS:85135243543
SN - 1470-2045
VL - 23
SP - e374-e384
JO - The Lancet Oncology
JF - The Lancet Oncology
IS - 8
ER -
